Search

Author/Creator Argollo, M

1. P124 Gastroenteropancreatic Neuroendocrine Neoplasms in patients with Inflammatory Bowel Disease: An ECCO CONFER Multicentre Case Series. (27th May 2021)

Authors:
Festa, S; Zerboni, G; Derikx, L; Ribaldone, D G; Dragoni, G; Buskens, C J; Nieveen van Dijkum, E; Pugliese, D; Panzuto, F; Krela-Kaźmierczak, I; Reiss, H; Shitrit, A B G; Chaparro, M; Gisbert, J P; Kopylov, U; Teich, N; Vainer, E; Nagtegaal, I; Hoentjen, F; Garcia, M J
Journal:
Journal of Crohn's and colitis
Issue:
Volume 15(2021)Supplement 1
Page Start:
S215
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. P342 Trans-continental analysis of over, 2000 Inflammatory Bowel Disease patients implicates geography, disease type, and exposure to immunosuppression as drivers of SARS-CoV-2 seroprevalence: data from the ICARUS-IBD Consortium. (21st January 2022)

Authors:
Wong, S Y; Helmus, D; Marlow, L; Martinez Pazos, V; Brann, S; Wellens, J; Kedia, S; Mak, J W Y; Bergemalm, D; Argollo, M; Zaltman, C; Steinwurz, F; Rubin, D; Allez, M; Halfvarson, J; Abreu, M T; Lindsay, J; Dutta, U; Silverberg, M S; Ng, S C
Journal:
Journal of Crohn's and colitis
Issue:
Volume 16(2022)Supplement 1
Page Start:
i357
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. P378 Rectal bleeding and stool frequency improvement with tofacitinib dose escalation to, 10 mg BID in patients with Ulcerative Colitis following loss of response on tofacitinib, 5 mg BID maintenance therapy: Results from OCTAVE Open. (21st January 2022)

Authors:
Allegretti, J R; Gecse, K B; Chiorean, M V; Argollo, M; Guo, X; Lawendy, N; Su, C; Mundayat, R; Paulissen, J; Salese, L; Irving, P M
Journal:
Journal of Crohn's and colitis
Issue:
Volume 16(2022)Supplement 1
Page Start:
i380
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. P477 Rectal bleeding and stool frequency improvement with tofacitinib retreatment in patients with Ulcerative Colitis after treatment interruption: Results from OCTAVE Open. (21st January 2022)

Authors:
Allegretti, J R; Gecse, K B; Chiorean, M V; Argollo, M; Guo, X; Lawendy, N; Su, C; Mundayat, R; Paulissen, J; Salese, L; Irving, P M
Journal:
Journal of Crohn's and colitis
Issue:
Volume 16(2022)Supplement 1
Page Start:
i446
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. P586 Vedolizumab in Mild to Moderate Crohn's Disease Patients Naïve to Biological Therapy: a Multicentric Observational Study. (30th January 2023)

Authors:
Dotti, A Z; Vilela, E G; Chebli, J M F; Chebli, L A; Magro, D O; Steinwurz, F; Argollo, M; Carvalho, N S; Parente, J M L; Parra, R S; Perin, R L; Flores, C; Morsoletto, E M; Ferreira, S D C; Ludvig, J C; Kaiser Jr, R L; Queiroz, N S F; Faria, M A G; Nicollelli, G M; Andrade, A R
Journal:
Journal of Crohn's and colitis
Issue:
Volume 17(2023)Supplement 1
Page Start:
i714
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗